Reaction Physical Therapy | |
1934 S Highway 66, Building C, Claremore, OK 74019-4371 | |
(918) 283-2527 | |
(918) 283-2569 |
Full Name | Reaction Physical Therapy |
---|---|
Type | Facility |
Speciality | Clinic/center - Physical Therapy |
Location | 1934 S Highway 66, Claremore, Oklahoma |
Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1013940626 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
225100000X | Physical Therapist | (* (Not Available)) | Secondary |
261QP2000X | Clinic/center - Physical Therapy | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Reaction Physical Therapy 1300 W Sam Houston Pkwy S, Suite 300, Houston, TX 77042-2447 Ph: (713) 297-7000 | Reaction Physical Therapy 1934 S Highway 66, Building C, Claremore, OK 74019-4371 Ph: (918) 283-2527 |
News Archive
SCOLR Pharma, Inc. today announced it has received a letter from the Food and Drug Administration identifying deficiencies regarding its Abbreviated New Drug Application for extended-release pseudoephedrine.
Only about 16 percent of U.S. adolescents have been fully vaccinated against human papillomavirus (HPV) by the time they turn 13, despite national recommendations that call for vaccination at 11 to 12 years of age.
A new and experimental anti-clotting drug, cangrelor, proved better than the commonly used clopidogrel and was significantly more effective at preventing blood clots in a large trial of patients who underwent coronary stent procedures.
Changes in the tissue environment of the breast that occur after pregnancy promote the metastasis of breast tumor cells. The paper by McDaniel et al., "Remodeling of the mammary microenvironment following lactation promotes breast tumor cell metastasis.
Otonomy, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced that researchers presented positive new data from a Phase 1b study of the company's lead product candidate, OTO-104, in patients with Meniere's disease.
› Verified 8 days ago